Philip Morris International Reports 2024 Fourth-Quarter & Full-Year Results
1. PMI posted a strong financial performance in 2024, with 14.2% revenue growth. 2. FDA approved ZYN nicotine pouches, boosting smoke-free product credibility and sales. 3. IQOS sales increased 12.6% in 2024, with significant market share gains in key regions. 4. Nicotine pouch shipments surged nearly 42% in the U.S., expanding market presence. 5. PMI forecasts continued growth in smoke-free products with a strong EPS outlook.